Aloracetam
![]() | |
Clinical data | |
---|---|
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
119610-26-3 ![]() |
PubChem (CID) | 178134 |
ChemSpider |
155069 ![]() |
UNII |
U0RKZ75D0T ![]() |
ChEMBL | CHEMBL2104637 |
Chemical and physical data | |
Formula | C11H16N2O2 |
Molar mass | 208.257 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Aloracetam (INN) is a drug described as a nootropic which is closely related to, but technically not of (as it lacks a pyrrolidone ring), the racetam family of compounds.[1][2][3] It was studied by Aventis for the treatment of Alzheimer's disease,[4] but was never marketed.
See also
References
- ↑ "The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" (PDF). World Health Organization. 2011. Retrieved 22 May 2015.
- ↑ Charles F. George (7 July 1998). Drug Therapy in Old Age. Wiley. ISBN 978-0-471-94149-1.
- ↑ C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 615–. ISBN 978-0-412-46630-4.
- ↑ Fischer F, Matthisson M, Herrling P. List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Diseases 2004;1:50–70.
This article is issued from Wikipedia - version of the 10/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.